1. Home
  2. ARVN vs CEPF Comparison

ARVN vs CEPF Comparison

Compare ARVN & CEPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARVN
  • CEPF
  • Stock Information
  • Founded
  • ARVN 2015
  • CEPF 2021
  • Country
  • ARVN United States
  • CEPF United States
  • Employees
  • ARVN N/A
  • CEPF N/A
  • Industry
  • ARVN Biotechnology: Pharmaceutical Preparations
  • CEPF Blank Checks
  • Sector
  • ARVN Health Care
  • CEPF Finance
  • Exchange
  • ARVN Nasdaq
  • CEPF Nasdaq
  • Market Cap
  • ARVN 676.2M
  • CEPF 580.3M
  • IPO Year
  • ARVN 2018
  • CEPF 2025
  • Fundamental
  • Price
  • ARVN $10.59
  • CEPF $10.37
  • Analyst Decision
  • ARVN Buy
  • CEPF
  • Analyst Count
  • ARVN 23
  • CEPF 0
  • Target Price
  • ARVN $17.80
  • CEPF N/A
  • AVG Volume (30 Days)
  • ARVN 2.3M
  • CEPF 165.7K
  • Earning Date
  • ARVN 11-05-2025
  • CEPF 01-01-0001
  • Dividend Yield
  • ARVN N/A
  • CEPF N/A
  • EPS Growth
  • ARVN N/A
  • CEPF N/A
  • EPS
  • ARVN N/A
  • CEPF 0.14
  • Revenue
  • ARVN $312,300,000.00
  • CEPF N/A
  • Revenue This Year
  • ARVN N/A
  • CEPF N/A
  • Revenue Next Year
  • ARVN N/A
  • CEPF N/A
  • P/E Ratio
  • ARVN N/A
  • CEPF $76.97
  • Revenue Growth
  • ARVN 93.86
  • CEPF N/A
  • 52 Week Low
  • ARVN $5.90
  • CEPF $10.09
  • 52 Week High
  • ARVN $27.00
  • CEPF $10.67
  • Technical
  • Relative Strength Index (RSI)
  • ARVN 59.44
  • CEPF N/A
  • Support Level
  • ARVN $9.27
  • CEPF N/A
  • Resistance Level
  • ARVN $11.51
  • CEPF N/A
  • Average True Range (ATR)
  • ARVN 0.53
  • CEPF 0.00
  • MACD
  • ARVN 0.02
  • CEPF 0.00
  • Stochastic Oscillator
  • ARVN 59.15
  • CEPF 0.00

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

About CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares

Cantor Equity Partners IV Inc is a blank check company.

Share on Social Networks: